La ricerca globale non è abilitata
Vai al contenuto principale

Indice degli argomenti

  • RAZIONALE

    The 12th "Milan Congress on Anticancer Innovative Therapy" Conference will involve leading international experts in the field of immuno-oncology and biologic therapy of cancer to improve the potential, opportunities and challenges of the new approaches.

    The increasing knowledge of the molecular mechanisms responsible for neoplastic progression, the characterization of tumor microenvironment, and the immunological/angiogenetic mechanisms regulating the tumor-host interaction, allowed us to identify and apply more effective anti-cancer biogical and immunological treatments.

    To date, the immuno-biotherapy is a continuously evolving treatment modality and it is currently integrated into the treatment algorythms of several different tumor types. The role of tumor metabolism and diet in tumor evolution and their impact on the outcomes of patients

    undergoing immunotherapy will be focused on.

    This conference explores topics that will appeal to clinicians, as well as, basic, translational, and clinical scientists ranging from academics to industry. As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, providing the audience with a broad overview of the most recent achievements in cancer biologic and immunologic therapy.

    Finally, a wide spectrum of evolving topics in cancer research such as epigenetic drugs, nanoparticles and CART cell-based new constructs will be analyzed in view on introducing them to the clinical setting.

  • 27th JANUARY 2022 · SCIENTIFIC PROGRAM

    14:50 Introduction

    Massimo Di Nicola (Milan, Italy)

    I SESSION: Preclinical evidences and new targets

    Chairmen: Filippo de Braud (Milan, Italy) - Soldano Ferrone (Boston, USA)

    15.00-16.00 Translational results in melanoma clinical trials - Ryan Sullivan (Boston, USA)

    16.00-16.10 Discussion

    16.10-16.40 Tumor vessels as gatekeepers for immune cells – implications for cancer immunotherapy - Anna Dimberg (Uppsala, Sweden)

    16.40-16.50 Discussion

    16.50-17.20 Overcoming immune suppression with next-generation CAR-T cells - Yvonne Chen (Los Angeles, USA)

    17.20-17.30 Discussion

    17.30-18.00 CAR-NK cells in solid tumors - Tamara Laskowski (Houston, USA)

    18.00-18.10 Discussion

    18.10-18.40 Keynote Lecture Cancer Nanomedicine and Transport Oncophysics - Mauro Ferrari (Menlo Park, California, USA) - Presented by Michele Del Vecchio (Milan, Italy)

    • 28th JANUARY 2022 · SCIENTIFIC PROGRAM

      II SESSION: Clinical translation

      Chairmen: Massimo Massaia (Cuneo, Italy), John Hiscott (Rome, Italy)

      15.30-16.00 TCR-modified T cells for anticancer adoptive therapy - Chiara Bonini (Milan, Italy)

      16.00-16.10 Discussion

      16.10-16.40 Defining the role of the CoREST complex in advanced breast cancer - Lluis Morey (Miami, USA)

      16.40-16.50 Discussion

      16.50-17.20 Modulation of microbiota to fight cancer - Maria Rescigno (Milan, Italy)

      17.20-17.30 Discussion

      17.30-18.00 CDK 4-6 inhibitors in breast cancer - Giulia Bianchi (Milan, Italy)

      18.00-18.10 Discussion

      18.10-18.40 Award for the best abstract

      18.40-19.00 Conclusions - Michele Del Vecchio (Milan, Italy)

    • FACULTY

      SCIENTIFIC HEADS

      FILIPPO DE BRAUD (Milan, Italy)
      MICHELE DEL VECCHIO (Milan, Italy)
      MASSIMO DI NICOLA (Milan, Italy)


      SCIENTIFIC BOARD

      GIOVANNI APOLONE (Milan, Italy)
      FILIPPO DE BRAUD (Milan, Italy)
      MICHELE DEL VECCHIO (Milan, Italy)
      MASSIMO DI NICOLA (Milan, Italy)
      GIANPIETRO DOTTI (Chapel Hill, USA)
      SOLDANO FERRONE (Boston, USA)
      JOHN HISCOTT (Rome, Italy)